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ABSTRACT 
 
 
 
Touza, Kaitlin Kyna. M.S., Purdue University, May, 2016. Intensive Treatment Near the 
End of Life in Advanced Cancer Patients. Major Professor: Kevin L. Rand. 
 
 
 
 Many advanced cancer patients receive intensive treatment near the end of life 
(EOL). Intensive treatment near the EOL is often associated with worse outcomes, such 
as worse quality of life (QOL), greater distress in patients and caregivers, and higher 
health care costs. For cancers typically unresponsive to chemotherapy such as lung and 
gastro-intestinal (GI), the side effects of intensive treatment are endured without 
increasing survival time. To date, research on EOL care in advanced cancer patients has 
focused on patient prognostic understanding, physician communication, and patient 
distress. These factors do not fully explain why many patients receive intensive treatment 
near the EOL when there is no hope for cure. Hence, there is a need to better understand 
the factors that influence EOL treatment in order to improve patient and caregiver 
outcomes. Self-Regulation Theory (SRT) provides a framework that may help explain 
motivations and care decisions in this population. This study had two aims: 1) to examine 
the associations between EOL clinical encounters (i.e., EOL conversations with a 
physician) and treatment intensity in advanced cancer patients near the EOL; and 2) to 
examine the associations between important SRT constructs (i.e., goal flexibility, hope, 
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and optimism) and treatment intensity in advanced cancer patients near the EOL. A 
sample of 76 advanced lung and GI cancer patients was recruited from Indiana University 
Simon Cancer Center. Hope predicted receiving chemotherapy closer to death (β = -.41, t 
(66) = -2.31, p = .025), indicating more intensive treatment near EOL. Other predictor 
variables were not significantly associated with intensive treatment. Implications and 
methodological limitations are discussed.
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INTRODUCTION 
 
 
 
When treating advanced cancer, physicians and patients must balance the pros and 
cons of intensive, survival-focused treatments versus symptom-directed treatments. 
Survival-focused treatments may prolong life but will likely limit functional status and 
reduce quality of life (QOL; Kypriotakis, Vidrine, Francis, & Rose, 2015). For example, 
the selection of chemotherapy involves a tradeoff between possible life prolongation and 
undesirable side effects (i.e., fatigue, pain, and gastro-intestinal [GI] changes; Emanuel et 
al., 2003). In contrast, symptom-directed treatments (i.e., palliative care) optimize QOL 
and function, but are thought to be associated with shortened survival (Kypriotakis et al., 
2015). However, there is evidence that early use of symptom-directed treatment actually 
increases survival time in patients with certain types of advanced cancer (Connor et al., 
2007; Kypriotakis et al, 2015; Scibetta, Kerr, Mcguire, & Rabow, 2015; Weeks et al., 
1998). Further, for typically unresponsive cancers (i.e., lung and GI cancers), intensive 
survival-focused treatments are associated with worse patient and caregiver QOL and 
greater caregiver distress and bereavement than symptom-directed treatments (e.g., 
palliative care and hospice; Leung et al., 2010; Martoni et al., 2007; Wright et al., 2008). 
Nonetheless, more than one-fifth of advanced lung and GI cancer patients forgo 
symptom-directed treatment and receive intensive treatment in the last three months of 
life (Earle et al., 2004; Emanuel et al., 2003; Martoni et al., 2007; McCarthy et al., 2003).    
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Advanced Lung and Gastrointestinal Cancer 
Advanced lung and GI cancer patients warrant specific attention in end of life 
(EOL) treatment trends due to the typical unresponsiveness of these cancers to 
chemotherapy and the high rate at which they occur (Braga et al., 2007; Emanuel et al., 
2003; Temel et al., 2008). In 2015, lung cancer accounted for between 13% and 14% of 
new cancers, and GI cancer 8%, making them the second and third most common cancers 
in the United States (American Cancer Society [ACS], 2015). Lung cancer accounted for 
more deaths than any other cancer (27% of cancer deaths), and GI cancer was the third 
most common killer (8 - 9% of cancer deaths) in 2015 (ACS, 2015). Only 15% of lung 
and 40% of GI cancer cases are diagnosed at a localized stage (i.e., before metastasis to 
distant organs; ACS, 2015). Long-term survival rates for these cancers decline 
dramatically when diagnosed at a later stage (ACS, 2015), making it important for 
physicians to discuss EOL and treatment outcomes with late stage patients. 
With the failure of first-line chemotherapies, advanced cancer patients will often 
go on to receive second- and third-line chemotherapies in their last months of life. 
Unfortunately for lung and GI cancers, subsequent chemotherapy regimens show poor 
response rates of less than 10%, and the likelihood of successful treatment declines with 
each additional chemotherapy regimen (Braga et al., 2007; Temel et al., 2008).  A 
prospective study examined a population of advanced non-small cell lung cancer 
(NSCLC) patients (N=40) and found that 30% of patients had started a new 
chemotherapy regimen in the last month of life (Temel et al., 2008).  
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Intensive Treatment Near End of Life in Advanced Cancer 
Commonly, the period of one to three months before death is defined as being 
near EOL (Braga et al., 2007; Earle et al., 2003, 2008; Grunfeld et al., 2006; Martoni et 
al., 2006; Temel et al., 2008). The most commonly used indicators of intensive treatment 
during this time period are: 1) number of ER visits; 2) number and duration of ICU 
admissions; 3) number and duration of hospitalizations; 4) time between death and 
hospice enrollment; 5) time between death and last chemotherapy administration; 6) time 
between death and most recent new chemotherapy regimen start; and 7) occurrence of 
intubation, tube feeding, or cardiopulmonary resuscitation (CPR; Braga et al., 2007; Earle 
et al., 2003, 2008; Martoni et al., 2006; Temel et al., 2008).  
The use of intensive treatment near EOL in advanced lung and GI cancers is 
concerning as survival-focused treatments are not consistently associated with greater 
survival time when compared to symptom-directed therapies (Connor, Pyenson, Fitch, 
Spence, & Iwaski, 2007; Mack et al., 2010). Weeks and colleagues (1998) examined 
prognostic understanding and treatment preferences in 917 advanced NSCLC patients 
and found that 6-month survival was no different for those who chose survival-focused 
treatment versus symptom-directed treatment. Kypriotakis and colleagues (2015) 
examined QOL as a predictor of survival in 512 advanced cancer patients with a median 
life expectancy of 14.2 months or less. Lung and GI cancer patients made up 58.7% of 
the sample. Counterintuitively, receipt of chemotherapy was associated with a 53% 
increased risk of dying within 24 months and better QOL predicted greater survival time. 
In a study of 4,493 terminally ill patients, Connor and colleagues (2007) found that 
patients enrolled in hospice survived a mean of 29 days longer than those not enrolled in 
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hospice. However, their sample included congenital heart failure patients, demonstrating 
the need to examine hospice versus non-hospice survival in cancer patients specifically. 
Patients are typically eligible for hospice enrollment when they are deemed 
terminally ill with a life expectancy of 6 months or less (Hospice Care, n.d.), but many 
advanced cancer patients are not enrolled in hospice until they are within days of death 
(Chen et al., 2003; McCarthy et al., 2003). The decision to forgo hospice predicts greater 
depression, prolonged grief disorder, and lower QOL in caregivers (Chen et al. 2003; 
Mack et al., 2010; Wright et al. 2008; Wright et al. 2010). In a study examining barriers 
to hospice enrollment among advanced lung and colorectal cancer (CRC) patients 
McCarthy and colleagues (2003) identified male gender, having non-Preferred Provider 
Organization (PPO) insurance, and living in a rural area as barriers. Chen and colleagues 
(2003) found multiple factors associated with hospice enrollment in advanced cancer 
patients, including age, education, household size, prognostic understanding, comorbid 
disease, and hospice discussion with a physician. Underutilization of hospice is 
concerning in advanced cancer as the findings of Kypriotakis and colleagues (2015) 
suggest QOL has an impact on overall survival time.  
Also of concern for patients and caregivers is the greater health care cost 
associated with intensive treatment near EOL and late hospice enrollment (Scibetta et al., 
2015; Zhang et al., 2009). Early referral and receipt of symptom-directed treatment (i.e., 
hospice) is associated with significantly lower health care costs and less emergent care 
use in the last month of life (Scibetta et al., 2015). 
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Factors Associated with End of Life Treatment in Advanced Cancer 
The care that patients receive near EOL is influenced by several factors, such as 
physician communication of terminal status, patient prognostic understanding, family 
status, affect, and age (Chen, Haley, Robinson, & Schonwetter, 2003; Fujisawa et al., 
2015; Mack et al., 2010; McCarthy et al., 2003; Weeks et al., 1998). Patients with 
inaccurate prognostic understanding (i.e., belief that cure is possible) are more likely to 
receive intensive treatment (Evans, Rasman, Deeg, & Onwuteaka-Philipsen, 2014; Haidet 
et al., 1998; Weeks et al., 2012). Yet even advanced cancer patients with accurate 
prognostic understanding and knowledge of their terminal status may still choose to 
receive intensive treatment near EOL, and previously-studied patient and physician 
factors do not explain why (Mack, Weeks, Wright, Block, & Prigerson, 2010).  
Patients who discuss prognosis with their physician (i.e., have an EOL clinical 
encounter) may be less likely to receive intensive treatment near EOL (Ahluwalia et al., 
2015; Loggers et al., 2013; Zhang et al., 2009). Ahluwalia and colleagues (2015) 
examined EOL clinical encounters as predictors of treatment intensity near EOL in 
advanced cancer patients. They found that patients who had early EOL clinical 
encounters (i.e., within the first month of diagnosis) were less likely to receive emergent 
care in their last month of life. Zhang and colleagues (2009) similarly found that 
advanced cancer patients who reported having an EOL clinical encounter were less likely 
to receive emergent care and had lower health care costs in their last week of life. In a 
study of 292 advanced cancer patients, Loggers and colleagues (2013) found that patients 
who reported an EOL clinical encounter did not receive emergent care near EOL. The 
results from these studies suggest EOL clinical encounters may result in less use of 
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emergent care near EOL. However, Ahluwalia and colleagues (2015) specifically 
examined EOL clinical encounters as predictors of chemotherapy use. They found that 
EOL clinical encounters were unrelated to use of chemotherapy. Also, Loggers and 
colleagues (2013) and Ahluwalia and colleagues (2015) found EOL clinical encounters to 
be unrelated to hospice care. The ability of EOL clinical encounters to predict treatment 
intensity near EOL should be further explored.  
The inconsistent ability of EOL clinical encounters to predict treatment intensity 
may be explained by inaccurate prognostic understanding. Even with physician- and 
patient-reported EOL clinical encounters, patients often overestimate the likelihood of 
long-term survival and misunderstand the goal of treatment as cure rather than life 
prolongation (Chen et al. 2003; El-Jawahri et al., 2014; Haidet et al., 1998; Weeks et al. 
1998; Weeks et al., 2012). Haidet and colleagues (1998) surveyed 520 CRC patients and 
their doctors in a prospective study examining patient preferences for EOL conversations, 
prognostic understanding, and treatment preferences. They discovered that EOL 
conversations did not improve the accuracy of patient-reported prognosis or physician 
understanding of patients’ EOL treatment preferences (e.g., preferences for CPR). Weeks 
and colleagues (1998) identified a relationship between patients’ survival estimates and 
preferences for treatment in NSCLC and CRC patients, such that patients with a more 
optimistic attitude toward prognosis preferred survival-focused treatment. In a recent 
study, Weeks and colleagues (2012) surveyed 1,193 advanced lung and CRC patients to 
examine their understanding of treatment goals and prognosis. They found that even with 
patient-reported EOL clinical encounters with physicians, most patients (69% of lung 
cancer patients and 81% of CRC patients) incorrectly believed the goal of treatment was 
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cure. Similarly, El-Jawahri and colleagues (2014) showed that 54% (N=50) of patients 
with advanced cancer believed that their cancer was likely to be cured.  
Advanced cancer patients’ predictions of survival time may guide their treatment 
choices. Weeks and colleagues (1998) examined predicted survival time in 917 advanced 
NSCLC and CRC patients and their treatment preferences. Patients were more optimistic 
about their survival than their physicians, with 59% of the patient sample estimating a 
90% chance of surviving six months. Optimistic survival estimates did not predict actual 
survival time. At six-month follow-up only 57% of these high estimators were still alive. 
Further, patients who were more optimistic about their predicted survival time were more 
likely to choose survival-focused treatment. Such attitudes about survival time and 
likelihood of successful treatment may be explained by optimistic bias, or the tendency 
for people to rate their own risk for negative outcomes as lower than that of others 
(Gouveia, & Clarke, 2001). Beyond general optimistic bias, there is a culture surrounding 
cancer that strongly encourages hopeful and optimistic attitudes in patients, with the 
expectation that optimistic outlooks may positively impact treatment outcomes (Sulmasy 
et al., 2010). However, in cases where cure is not possible, hopeful and optimistic 
attitudes about survival may lead to worse outcomes. 
Hopeful and optimistic attitudes toward survival and cure are likely due to 
multiple physician and patient factors (Hagerty et al., 2004; Haidet et al., 1998). 
Physicians may be unwilling or uncomfortable relating prognostic information to patients 
with no chance of cure, such that they use overly optimistic language or avoid the 
discussion until death is imminent (Gattellari, Voigt, Butow, & Tattersall, 2002; Hagerty 
et al., 2004; Haidet et al., 1998; Weeks et al., 2012). In an Australian study examining 
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EOL clinical encounters with physicians in 118 advanced cancer patients, Gattellari and 
colleagues (2002) found that only 75% of patients had been informed that their disease 
was incurable, 58% had been told about life expectancy, 44% were presented with 
treatment options alternative to survival-focused treatment, only 36% were informed of 
how survival-focused treatment would impact QOL, and understanding was assessed 
with only 10% of patients. Factors such as affect may impact patient readiness to engage 
in EOL discussions. Hagerty and colleagues (2004) examined patient differences in 
preferences for prognostic information. They noted that more depressed patients were 
more likely to want information on average survival and shortest survival times without 
treatment. These findings imply that patients with less optimistic or hopeful outlooks are 
more open to addressing EOL issues and that there are patient and/or physician factors 
impacting care decisions beyond prognostic understanding. Such trends also highlight the 
importance of controlling for psychological distress in analyses of factors impacting 
patient treatment choice. 
In patients who express accurate prognostic understanding, social factors, affect, 
and personality traits may influence their decision (El-Jawahri et al., 2014; Hagerty et al., 
2004; Weeks et al., 1998). Mack and colleagues (2010) examined prognostic 
understanding in advanced cancer patients and their EOL treatment preferences. They 
found that among patients who had accurate understanding of their terminal diagnosis, 
17% (N=121) wished to receive survival-focused treatment, suggesting patient 
personality traits might impact treatment beyond prognostic understanding. There is 
currently no theoretical framework explaining how personality may impact treatment 
near EOL in advanced cancer patients. 
9 
 
Self-Regulation Theory 
Self-Regulation Theory (SRT) is an empirically supported model of human 
behavior that may help explain how patients choose care near EOL (Carver & Scheier, 
1998). According to SRT, human behavior is driven by the pursuit of goals. SRT 
constructs (i.e., goal-related personality traits) may provide a first step in predicting 
advanced cancer patients’ EOL treatment choices (Carver & Scheier, 1998).  
SRT is based on expectancy-value models of motivation (Carver & Scheier, 
1998). Goals are characterized by value and expectancy, such that the decision to pursue 
a goal is a function of the expectancy that a goal can be achieved and the value placed on 
its achievement (Carver & Scheier, 1998; Rasmussen, Wrosch, Scheier, & Carver, 2006). 
For goals with high value, the decision to pursue a goal may be maintained even if 
expectancy for success is low (Carver & Scheier, 1998). An advanced cancer patient’s 
decision to pursue survival-focused treatment despite low expectancy of success and 
decreasing QOL may be explained by the high value of survival (Scheier & Carver, 
2003). 
Goal-Related Personality Traits 
SRT posits that what goals are valued and pursued can be further influenced by 
goal-related personality traits, such as goal flexibility, hope, and optimism (Carver & 
Scheier, 1998). Goal flexibility is a two-part process in which a person disengages from 
goals when they become unattainable and reengages with new more achievable goals 
(Wrosch, & Scheier, 2003; Wrosch, Scheier, & Miller, 2013). The ability to disengage 
from unattainable goals is adaptive and has a positive impact on subjective well-being 
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(Wrosch et al., 2013), and greater goal flexibility is associated with less psychological 
distress (Carver & Scheier, 1998; Wrosch, Scheier, Miller, Schulz, & Carver, 2003; 
Wrosch et al., 2013).  
Goal disengagement and reengagement appear to be distinct processes in that 
individuals differ in their ability to adjust their goals. Goal disengagement appears to 
protect against the experience of repeated failure in persisting toward an unattainable goal 
and relieve negative aspects of subjective well-being (e.g., negative affect). Goal 
reengagement appears to foster positive aspects of subjective well-being (e.g., positive 
affect) through the pursuit of new meaningful attainable goals (Wrosch et al., 2003; 
Wrosch et al., 2013; Wrosch & Sabiston, 2013).  
No studies examining goal flexibility in the context of advanced cancer were 
discovered during the course of this research. While continuing to believe that cure is 
possible may be an indication of psychological well-being, SRT posits that the inability 
to progress toward a goal is a major cause of psychological distress such that limited goal 
flexibility and maintaining the goal of cure may lead to depressive symptoms (Carver & 
Sheier, 1998; Rasmussen et al., 2006; Wrosch et al., 2013). Patients higher in goal 
disengagement may be more likely to disengage from cure goals and receive less 
intensive treatment near EOL. Patients higher in goal reengagement may be more likely 
to pursue symptom-directed treatment as it may allow engagement in alternate goals, 
such as optimizing QOL.  
Trait hope and optimism are also typically associated with positive health 
outcomes (Berg, Snyder, & Hamilton, 2008; Feldman & Sills, 2013; Snyder, Lehman, 
Kluck, & Monsson, 2006). However, how these personality traits impact EOL cancer 
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treatment has not been explored. Hope is defined as a person’s perceived ability to 
achieve goals. It comprises two interrelated thought processes: 1) a person’s belief in 
their ability to generate pathways to achieve a goal; and 2) a person’s belief in their 
determination to use those pathways (Snyder, 2002). Optimism is the trait expectancy for 
positive outcomes (Scheier & Carver, 1985). It is the belief that good, as opposed to bad, 
things will happen in the future.  
Hopeful and optimistic people have greater expectancy for positive outcomes in 
goal achievement and are more persistent in goal pursuits in the face of barriers (Carver 
& Scheier, 1998; Rasmussen et al., 2006). Snyder and colleagues (2005) demonstrated 
that hopeful people endure pain longer than less hopeful people. Geers, Wellman, 
Seligman, Wuyek, and Neff (2010) showed that greater optimism is associated with 
greater treatment adherence when patients rated their treatment goals as highly important. 
Trait hope and optimism may help explain why some advanced cancer patients persist in 
survival-focused treatment despite worsening QOL. Further, these traits may influence 
what treatment goals are perceived as attainable versus unattainable, potentially 
explaining why advanced cancer patients maintain the goal of cure. 
High levels of hope and optimism may increase patients’ expectancy of successful 
treatment, such that they pursue the goal of survival despite health decline (Weeks et al., 
1998). In a survey of 73 NSCLC patients’ attitudes toward hypothetical intensive 
chemotherapy regimens, most patients were willing to accept intensive chemotherapy 
despite only a small chance of cure or life prolongation (Hirose et al., 2008). This 
suggests a hopeful or optimistic bias in expectations for treatment success. Similarly, in 
Weeks and colleague’s (1998) study of 917 advanced cancer patients, those who were 
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more optimistic about their six-month survival were more than twice as likely to favor 
survival-focused treatment.  
Present Study 
Why patients with incurable cancer often choose survival-focused treatment over 
symptom-directed treatment is not well understood (Chen et al. 2003; El-Jawahri et al., 
2014; Haidet et al., 1998; Mack et al., 2010; McCarthy et al., 2003; Weeks et al. 1998; 
Weeks et al., 2012). EOL clinical encounters (e.g., EOL prognostic discussion with a 
physician) and goal-related personality traits (e.g., goal flexibility, hope, and optimism) 
may impact what treatment goals are valued, such as prolonging life or greater comfort 
near EOL. Goal flexibility, hope, and optimism have been shown to predict goal pursuit 
in heart disease, early stage breast cancer, multiple sclerosis, diabetes, and amputation, 
but the majority of this research focuses on recovery post treatment or coping with a 
chronic disease (Coffey, Gallagher, & Desmond, 2014; Madan & Pakenham, 2014; 
Rasmussen et al., 2006). There is currently no conceptual framework that explains how 
these factors impact treatment in advanced cancer patients. Understanding what factors 
play a role in choosing survival-focused treatment over symptom-directed treatment may 
help physicians to effectively communicate prognosis and treatment options and help 
patients to make informed health care decisions (Hagerty et al., 2004; Mack et al., 2010). 
 To date, research on EOL treatment in advanced cancer patients has largely 
focused on prognostic understanding, physician communication, and patient distress. 
These factors do not fully explain why many patients receive intensive treatment near 
EOL when there is no hope for cure. EOL clinical encounters and goal flexibility, hope, 
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and optimism may predict EOL treatment in advanced cancer patients. The purpose of the 
current study was to examine if EOL clinical encounters (i.e., EOL conversations with a 
physician) and SRT constructs (i.e. goal flexibility, hope, and optimism) predict intensity 
of treatment received near EOL in advanced cancer patients (Figure B1). I tested the 
following research questions and hypotheses: 
Research Question 1: Do EOL clinical encounters (i.e., patient-reported EOL treatment 
goals conversations and evidence of EOL conversations in the medical record) predict 
intensity of treatment near EOL?   
Hypothesis 1.1: Patient-reported EOL treatment goals conversation with a 
physician will predict less intensive treatment near EOL. 
Hypothesis 1.2: Evidence of EOL conversation from medical records will predict 
less intensive treatment near EOL. 
Research Question 2: Do patient personality traits (i.e., goal flexibility, hope, and 
optimism) predict intensity of treatment near EOL? 
Hypothesis 2.1: Greater goal disengagement and goal reengagement will predict 
 less intensive treatment near EOL. 
Hypothesis 2.2: Greater hope and optimism will predict more intensive treatment 
 near EOL. 
14 
 
METHOD 
 
Study Design 
This study used a longitudinal correlational design. Participants were tracked 
from consent (March 2010) until data collection was halted (February 2015). An 
electronic medical record (EMR) review was performed with deceased participants’ 
records (Table A1). The outcome variable was use of intensive treatment. EOL clinical 
encounters (i.e., patient-reported EOL treatment goals conversations and evidence of 
EOL conversations from medical records) and personality traits (i.e., goal flexibility, 
hope, and optimism) were predictors, measured via EMR review and self-report survey. 
Survey measures and interview data were collected at the Indiana University Simon 
Cancer Center between March 2010 and July 2011. This project examined data from a 
larger study with the aim of examining relationships among goals, goal-related 
personality traits, situational factors, and health care decision-making. The study protocol 
was approved by the Institutional Review Board (IRB) of Indiana University – Purdue 
University Indianapolis (IUPUI). 
Setting and Sample 
Participants were recruited from the Indiana University Simon Cancer Center 
Thoracic Oncology and Gastrointestinal Oncology Clinics. Co-investigators and 
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attending oncologists screened clinic schedules for potentially eligible patients. Between 
March 2010 and July 2011, 170 potentially eligible patients were identified (Figure B2). 
Of these 170 patients, 17 were not given a study packet at their physician’s discretion, the 
research assistant was unable to approach them before the recruitment window ended, or 
they were deceased. The remaining 153 patients were mailed a study invitation packet 
including an introduction letter, survey, and informed consent documents. Of these 
patients, 36 refused participation, 11 were deceased, and 22 were lost to follow-up, 
resulting in a sample size of 84. Potentially eligible participants were approached during 
a clinic visit to confirm eligibility and obtain informed consent. At the time data 
collection was halted in February 2015, 8 patients were alive and were excluded from the 
analyses. Of these remaining 76 participants, 70 completed survey measures and were 
included in the analyses.  
Eligibility Criteria 
  Eligible patients had been diagnosed with advanced lung or GI cancer determined 
by histological confirmation of cancer, had clinical evidence of metastatic disease 
without option of curative resection, had an expected overall survival of less than 12 
months, were enrolled within 8 weeks of diagnosis, were greater than 18 years of age, 
were English speaking, were able to provide informed consent, and were willing to 
complete study surveys. Consistent with the expected overall survival requirement, 
patients with GI cancers had to have previously received a first line chemotherapy at 
consent.  
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Measures 
 Participants were asked to fill out a self-report survey including measures of 
demographics, EOL clinical encounters, goal-related personality traits, and psychological 
distress. 
Sample Characteristics 
 Participant demographics were assessed via self-report survey. Participants were 
asked to report their age, gender, race/ethnicity, education level, marital status, and 
insurance type (Table A2). 
End of Life Clinical Encounters 
 An item on the survey assessed for patient-reported EOL treatment goals 
conversations, (e.g., “Have you and your oncologist discussed any particular wishes you 
have about the care you would want to receive if you were dying?”). EMR records were 
reviewed for evidence of EOL conversations with a physician. 
Goal-Related Personality Traits 
 Hope was assessed using the Adult Hope Scale (AHS; Snyder et al., 1991), a 12-
item self-report measure of trait hope (i.e., “Even when others get discouraged, I know I 
can find a way to solve a problem.”). Responses range from “definitely false” to 
“definitely true” on an eight point Likert-type scale. Higher scores indicate greater levels 
of hope. The AHS showed good internal consistency in this sample (Cronbach’s alpha = 
0.84).  
Optimism was assessed using the Life Orientation Test-Revised (LOT-R; Scheier, 
Carver, & Bridges, 1994), a10-item self-report measure of dispositional optimism (i.e., 
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“In uncertain times, I usually expect the best.”). Responses range from “strongly 
disagree” to “strongly agree” on a five point Likert-type scale. Higher scores indicate 
greater levels of optimism. The LOT-R is revised from the original LOT (Scheier & 
Carver, 1985). The LOT-R showed good internal consistency in this sample (Cronbach’s 
alpha = 0.82). 
Goal flexibility was assessed using the Goal Adjustment Scale (GAS; Wrosch et 
al., 2003), a 10-item measure of ability to disengage and re-engage with goals. Responses 
range from “almost never true” to “almost always true” on a five point Likert-type scale. 
The measure produces two subscales for goal disengagement (i.e., “I find it difficult to 
stop trying to achieve the goal.”) and goal reengagement (i.e., “I put effort toward other 
meaningful goals.”). The goal disengagement and goal reengagement subscales showed 
acceptable internal consistency in this sample (Cronbach’s alpha = 0.64 and 0.94, 
respectively). 
Covariates 
Age, gender, distress, and performance status were controlled for in all analyses. 
Psychological distress was measured using the Hospital Anxiety and Depression 
Scale (HADS), a widely used 14-item measure assessing anxiety (i.e., “I feel tense or 
‘wound up.’”) and depression (i.e., “I feel as if I am slowed down.”) in ill patients 
(Zigmond & Snaith, 1983). A total score can also be used to assess global distress 
(Marinez Lopez et al., 2012). The HADS uses a four point Likert-type scale (ranging 
from 0 to 3) with higher scores indicating more anxiety and depression. In this sample, 
the HADS had good internal consistency (Cronbach’s alpha = 0.88). 
18 
 
Oncologists were asked to rate participants’ functioning. The Eastern Cooperative 
Oncology Group (ECOG) Performance Status scale is used by doctors and researchers to 
assess how a patient's disease affects their daily living and self-care activities (i.e., “0 = 
Fully active, able to carry on all pre-disease performance without restriction.”; Oken et 
al., 1982). Responses range from “fully active” to “dead” on a five-point scale. Physician 
responses were verified via EMR review.  
Indicators of Intensive Treatment 
EMR review was conducted to extract data on treatments received for each 
participant (i.e., between consent and death), treatments received near EOL (i.e., within 6 
months of death), and evidence of EOL clinical encounters with a physician. Indicators of 
intensive treatment were defined based on prior research (Braga et al., 2007; Earle et al., 
2004; Temel et al., 2008).   
Dichotomous indicators for intensive treatment include: 1) more than one day 
spent in an intensive care unit (ICU)/emergency room (ER) and/or hospital within 30 
days of death; 2) more than one admission to an ICU/ER and/or hospital within 30 days 
of death; 3) enrollment in hospice within 7 days of death; 4) chemotherapy administration 
within 30 days of death; and 5) new chemotherapy regimen start within 60 days of death 
(Table A3; Braga et al., 2007; Earle et al., 2004; Temel et al., 2008).  
Continuous indicators of intensive treatment include: 1) days spent in an ICU/ER 
and/or hospital within 30 days of death; 2) number of ICU/ER and/or hospital admissions 
within 30 days of death; 3) days between hospice enrollment and death; 4) days between 
final chemotherapy administration and death; and 5) days between final chemotherapy 
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regimen start and death (Table A4; Earle et al., 2004; Temel et al., 2008). Evidence of 
less intensive treatment will be indicated by: 1) less use of emergent care within 30 days 
of death; 2) greater time spent in hospice care; 3) greater time between final 
chemotherapy administration and death; and 4) greater time between final chemotherapy 
regimen start and death; (Braga et al., 2007; Earle et al., 2004; Temel et al., 2008). 
Procedure 
 Eligible participants were mailed an introduction packet, including an invitation 
letter, informed consent document, and surveys. Participants were then approached in 
clinic to confirm eligibility and obtain informed consent. Consent included access to 
medical records. EMR records were reviewed for deceased patients. Study surveys were 
completed by patients individually and returned to a research assistant during clinic 
visits. Indiana University Simon Cancer Center used two electronic medical record 
systems: Careweb and Indiana Network for Patient Care (INPC). Medical records in both 
databases were reviewed for each participant. 
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RESULTS 
 
 
 
Data Cleaning  
 Continuous variables were examined for skewness and kurtosis (Table A4). The 
following outcome variables were positively skewed and leptokurtic: 1) total days 
inpatient in the ER/ICU and/or hospitalized within 30 days of death; 2) total number of 
admissions to the ER/ICU and/or hospitalized within 30 days of death; 3) days between 
hospice admission and death; 4) days between final chemotherapy administration and 
death; and 5) days between final chemotherapy regimen start and death. Zero order 
correlations between predictor and control variables are presented in Table A5. 
 Homoscedasticity was assessed via scatterplot. Hope, days spent on hospice, days 
between final chemotherapy administration and death, days between final chemotherapy 
regimen start and death, and days spent in an inpatient setting in the last 30 days of life 
contained outliers greater than three standard deviations from the mean. These outliers 
represented accurate values for medical record event data and were within the possible 
range of scores for the survey measures. The impact of these outliers was examined by 
Winsorizing them to three standard deviations (Ghosh & Vogt, 2012). Analyses were run 
twice, once with the Winsorized values and again with the non-transformed data. 
Winsorizing affected significance in the analysis examining personality traits as  
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predictors of days between final chemotherapy administration and death. Therefore, 
Winsorized data were used in all analyses.  
Descriptive Analyses 
 Final analyses included 70 participants who had completed survey measures and 
had died before data collection was halted (Figure B2). Participant demographics are 
presented in Table A2. Participants survived a median 280 days from consent. Of these 
70 participants who completed the survey, 8.5% reported having an EOL conversation 
with their physician, while 89.5% of medical records contained documentation of an EOL 
conversation (Table A3). Consenters were compared to patients who refused participation 
on age, race/ethnicity, gender, and cancer type. Patients who refused participation were 
significantly older than consenters (66.08 vs. 59.92 years; t (110) = 2.58, p = 0.011). 
There were no differences on race/ethnicity, gender, or cancer type. 
 Hospice enrollment or the decision to forgo enrollment was often not recorded in 
the medical record resulting in a large number of unknown cases. Because of this, the 
analyses examining hospice enrollment included only 42 participants. Analyses 
examining personality variables as predictors of days between the final chemotherapy 
administration or regimen start and death included 67 participants as 3 participants did 
not receive chemotherapy. One survey participant did not answer the question regarding 
patient-reported clinical encounters, as such analyses examining EOL clinical encounters 
as predictors of emergent care and chemotherapy use include one less participant.  
 Days spent in an ICU, ER, or hospital within 30 days of death were also poorly 
documented in that there was often unclear documentation of intake setting (i.e., ER or 
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ICU) and eventual release or transfer from the ER/ICU to inpatient hospitalization. These 
were also low frequency events. Therefore these variables were combined to create two 
composite variables: 1) total days spent in an emergent care setting within 30 days of 
death; and 2) total admissions to an emergent care setting within 30 days of death.  
 A substantial portion of the sample had an intensive treatment indicator near 
EOL. For dichotomous treatment related variables: 1) 38.2% of participants received 
intensive treatment; 2) 18.4% received chemotherapy within 30 days of death or started a 
new chemotherapy regimen within 60 days of death; and 3) 30.3% used emergent care 
within 30 days of death (Table A3). For continuous variables: 1) the mean days spent in 
the ER/ICU or hospitalized within 30 days of death was 2.39 (SD = 4.22); 2) the mean 
number of admissions to the ER/ICU within 30 days of death was .62 (SD = .78); 3) the 
mean days between hospice admission and death was 42.2 (SD = 70.25); 4) the mean 
days between last chemotherapy admission and death was 149.79 (SD = 209.76); 5) and 
the mean days between starting a new chemotherapy regimen and death was 240.36 (SD 
= 231.25; Table A4).  
Hypothesis Testing 
Research Question 1 Results 
 Research question one asked if EOL clinical encounters (i.e., EMR documented 
EOL conversations and patient-reported EOL treatment goals conversations) would 
predict intensity of treatment near EOL. Hypotheses 1.1 and 1.2 stated that the presence 
of an EOL clinical encounter (i.e., patient-reported or EMR documented, respectively) 
would predict less intensive treatment. To test these hypotheses three hierarchical logistic 
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regression analyses (Table A6) and five hierarchical linear regression analyses (Table 
A7) were performed (one regression for each indicator of treatment intensity).  Age, 
gender, performance status, and distress were controlled for in all analyses.  
 In all three logistic regressions, EOL clinical encounters did not predict treatment 
intensity. Neither patient-reported EOL goals conversations nor EMR documented EOL 
conversations predicted: 1) treatment intensity (Table A10); 2) receiving chemotherapy 
within 30 days of death and/or starting a new chemotherapy regimen within 60 days of 
death (Table A11); or 3) use of emergent care within 30 days of death (p > .05; Table 
A12). Performance status had a significant positive relationship with both treatment 
intensity (Table A10) and emergent care use within 30 days of death (p =.049 and p = 
.027, respectively; Table A12). With each level increase in performance status, patients 
were 2.43 times more likely to receive intensive treatment and 3.06 times more likely to 
use emergent care within 30 days of death. Other control variables did not have a 
significant relationship with the outcome variables in these analyses (p > .05). 
 Next, a series of five linear regressions was performed to examine whether EOL 
clinical encounters predict various indicators of treatment intensity (Table A7). EOL 
clinical encounters were not significant predictors of intensive treatment in these five 
analyses. Neither patient-reported EOL goals conversations nor EMR documented EOL 
conversations were significantly related to: 1) total days spent in an emergent care setting 
(i.e., in an ER/ICU and/or hospital) within 30 days of death (Table A13); 2) total 
admissions to an emergent care setting within 30 days of death (Table A14); 3) days on 
hospice (Table A15); 4) days between the final chemotherapy administration and death 
(Table A16); or 5) days between the final chemotherapy regimen start and death (Table 
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A17; p > .05). Gender was a significant predictor of total days in an inpatient setting in 
the last 30 days of life, such that women spent an average of 1.90 more days inpatient 
than men during this period (p = .045; Table A13). Gender trended toward significance in 
predicting total inpatient admissions in the last 30 days of life (p = .057; Table A14), also 
indicating greater treatment intensity for women. Other control variables were not 
significantly related to outcomes (p > .05). 
Research Question 2 Results 
 Research question two asked if goal-related personality traits would predict 
treatment intensity near EOL. Hypothesis 2.1 stated that higher levels of goal 
disengagement and goal reengagement would predict less intensive treatment. Hypothesis 
2.2 stated that higher levels of hope and optimism would predict more intensive 
treatment. To test these hypotheses, three hierarchical logistic regression analyses (Table 
A8) and five hierarchical linear regression analyses (Table A9) were performed (again, 
one regression for each indicator of treatment intensity). Age, gender, ECOG status, and 
distress were controlled for in all analyses.  
 Goal-related personality traits were not significant predictors of: 1) dichotomous 
treatment intensity (Table A18); 2) receiving chemotherapy within 30 days of death 
and/or starting a new chemotherapy regimen within 60 days of death (Table A19); or 3) 
use of emergent care within 30 days of death (p > .05; Table A20). However, 
performance status had a noticeable effect size in predicting dichotomous treatment 
intensity (Odds Ratio = 2.20) and use of emergent care within 30 days of death (Odds  
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Ratio = 2.64) and trended toward significance in these analyses (p = .086 and p = .062, 
respectively).  
 For the first linear regression analysis, goal-related personality traits were 
examined as predictors of total days spent in an emergent care setting (i.e., in an ER/ICU 
and/or hospital) within 30 days of death (Table A21). Hope, optimism, and goal 
disengagement were not significant predictors of inpatient days (p > .05). Goal 
reengagement did have a significant positive relationship with the emergent care variable 
such that a one point increase in goal reengagement corresponded to .30 more days spent 
in an inpatient setting within 30 days of death, β = .38, t (70) = 2.54, p = .014. Optimism 
had a noticeable effect size in this analysis (β = -.31) and trended toward significance (p 
= .051). The control variables, age, gender, ECOG status, and distress, were not 
significantly related to the outcome (p > .05). 
 In the second linear regression, goal-related personality traits were used to predict 
total inpatient admissions within 30 days of death (Table A22). Personality traits were not 
significant predictors of inpatient admissions (p > .05). However, goal reengagement 
trended toward significance (p = .083). Control variables were not significantly related to 
the outcome (p > .05). 
 The third linear regression examined goal-related personality traits as predictors 
of days spent on hospice (Table A23). None of the personality traits or control variables 
were related to days on hospice (p > .05).  
 In the fourth linear regression, which examined goal-related personality traits as 
predictors of days between final chemotherapy administration and death, hope was 
significantly related to the outcome (Table A24). For each one point increase in hope, 
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participants had an average of 8.98 fewer days between their last chemotherapy 
administration and death, β = -.41, t (67) = -2.31, p = .025. Other personality variables 
and controls were not related to the outcome (p > .05).  
 The fifth linear regression examined goal-related personality traits as predictors of 
days between final chemotherapy regimen start and death (Table A25). None of the 
personality traits were significant predictors. However, hope and goal disengagement 
trended toward significance (β = -.33, t (67) = -1.90, p = .062 and β = -.27, t (67) = -1.88, 
p = .065, respectively). Control variables were not significantly related to the outcome (p 
> .05). 
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DISCUSSION 
 
 
 
 The goal of this study was to examine EOL clinical encounters (i.e., patient-
reported and EMR documented EOL conversations with a physician) and goal-related 
personality traits (i.e., hope, optimism, goal disengagement, and goal reengagement) as 
predictors of treatment intensity near EOL in advanced cancer patients. I hypothesized 
that both patient-reported EOL clinical encounters and the documentation of EOL 
discussions in the EMR would predict less intensive treatment. I also hypothesized that 
greater goal disengagement and reengagement would predict less intensive treatment, 
while greater hope and optimism would predict more intensive treatment. The hypotheses 
were generally not supported.  
 Methodological concerns may account for the undetected relationship between 
patient personality or EOL conversations on the one hand, and EOL treatment intensity 
on the other. Null results in the majority of the analyses may be a result of lack of power 
due to the small sample size and relatively high number of predictors. Uneven 
distributions in dichotomous predictor variables also make it difficult to detect signal 
(Aguinis, Beaty, Boik, & Pierce, 2005; Shieh, 2009). For example, patient reported EOL 
clinical encounters had an uneven distribution between those who reported having a 
clinical encounter (n = 6) and those who did not (n = 63). The same is true for EMR 
documented EOL clinical encounters. Because of the uneven frequency split in the EOL 
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clinical encounter variables, it is difficult to interpret the results in the analyses 
examining them as predictors (Aguinis, Beaty, Boik, & Pierce, 2005; Shieh, 2009). 
 The analyses examining EMR documented EOL clinical encounters are further 
complicated by possible reverse causality. The EMR was searched from diagnosis of 
advanced cancer till death for evidence of EOL conversations between physicians and 
patients. Patients who are closer to death may be more likely to discuss EOL with their 
physician. It is thus likely that EMR document EOL conversations occurred following or 
in conjunction with intensive treatment near EOL. Therefore, the method by which EMR 
documented EOL clinical encounters were collected resulted in this variable being 
uninterpretable as a predictor of EOL treatment intensity.  
The relationship between performance status and intensive treatment is also 
difficult to interpret. Performance status was significantly and positively related to overall 
treatment intensity and use of emergent care within 30 days of death in analyses 
examining EOL clinical encounters as predictors (p = .049 and p = .027, respectively). 
Patients with poorer functionality (i.e., higher ECOG rating) received more intensive 
treatment. Performance status was not a significant predictor of treatment intensity or 
emergent care use near EOL in analyses examining goal-related personality traits. 
However, performance status trended toward significance in both analyses (p = .086 and 
p = .062, respectively). The relationship of performance status with treatment intensity 
and emergent care in both sets of analyses (i.e., with EOL clinical encounters and goal-
related personality traits as predictors) suggests patients who are in poorer health receive 
more intensive treatment and use emergent care close to death. It is difficult to determine 
if poorer health reflected by performance status and use of emergent care is the result of 
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side effects of the treatments being received or an indicator of disease severity 
independent of treatment. 
The analyses may have been further complicated by unavoidable measurement 
error. Medical record information is often incomplete and many of the treatment 
variables examined are low frequency events (Sikorskii et al., 2012). It was unclear if the 
absence of documentation in the EMR represents a true nonexistence of an event or the 
event simply not being recorded. In this study missing data was coded such that the 
absence of documentation indicated an event had not occurred. To illustrate, a participant 
may have attended an ER or hospital during their last 30 days of life that was not 
connected to the Careweb and INPC systems. In cases like this, emergent care near EOL 
would have not been detected and would have been coded to indicate that the participant 
did not receive emergent care near EOL. Misclassified events such as these may result in 
either overestimating or underestimating the strength of the relationship between 
predictor and outcome variables, increasing the likelihood of either type 1 and type 2 
errors (Gill, Laporte, & Coyte, 2013; Preston et al., 2013).   
The problems of missing event data and small sample size are particularly evident 
in examining hospice enrollment. The detection of hospice enrollment in this study 
depended on notations in the medical record. Many medical records failed to record 
hospice enrollment or the decision to forgo enrollment which left a large portion of cases 
listed as unknown. Beyond small sample size, the large portion of unknown cases for 
hospice enrollment likely resulted in an incorrect estimation of overall use of hospice in 
this sample. 
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Power may have been further limited by restriction of range in continuous 
variables (Kazdin, 1998). The measures of hope, optimism, and goal flexibility have not 
been validated in advanced lung and GI cancer patients. Because cancer patients are 
encouraged to maintain positive attitudes in the face of their disease, these measures may 
pull for specific patterns of responding (Breetvelt & Van Dam, 1991; O’Leary, Diller, & 
Recklitis, 2007; Sulmasy et al., 2010). Therefore, responses on the personality measures 
may not reflect true levels of hope, optimism, and goal flexibility across the sample. 
Further, outliers were Winsorized and this brought skew and kurtosis values within 
acceptable limits. However, Winsorizing likely restricted the range of continuous 
variables such that the ability to detect significance in relatinships between predictor and 
control variables was reduced (Duan, 1999; Ghosh & Vogt, 2012). This may have 
resulted in higher type 2 error rates. Other data transformation methods, such as 
logarithmic transformation, may have preserved more power for analysis (Duan, 1999; 
Ghosh & Vogt, 2012). 
Theoretical Explanations 
The above mentioned power limitations should be considered when interpreting 
the results of the analyses presented below. Documented and patient-reported EOL 
clinical encounters did not predict use of intensive treatment in this study. The 
relationship between documented EOL clinical encounters and intensity of treatment may 
be complicated because as patients spend more time in the hospital, an emergent care 
setting, or pursuing survival-focused treatment they may be more likely to discuss EOL 
care with their physician. Patient-reported EOL conversations were timeline dependent 
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because patients were asked about these encounters on the self-report survey. 
Documented EOL clinical encounters were not restricted in this way, so that at any point 
after consent doctors may have had such conversations with their patients and 
documented it. Hence, there was a relatively high rate of EMR documented EOL 
conversations compared to patient-reported EOL conversations. The higher rate of EMR 
documented EOL conversations does not necessarily imply these discussions were early 
or timely. Further, the uneven frequency distribution for both EMR documented and 
patient reported EOL clinical encounters makes interpretation of these results difficult. 
However, methodological issues aside, EOL clinical encounters may not be good 
predictors of treatment intensity. Doctor-reported EOL conversations have been shown to 
be a poor indicator of patient prognostic understanding such that documented 
conversations may not be capturing patients’ attitudes and understandings of such 
encounters (Weeks et al., 2012). For this study, these clinical encounters were not audio 
recorded so the quality and extent of these discussions is unknown.  
 Most analyses examining personality traits as predictors of treatment intensity 
also did not display significance. The lack of significance findings in the relationship 
between goal-related personality traits and treatment intensity may reflect the true state of 
nature. While traits such as hope, optimism, and goal flexibility have been shown to 
relate to treatment outcomes in certain diseases (i.e., breast cancer, heart disease, pain, 
and diabetes; Madan & Pakenham, 2014; Rasmussen et al., 2006; Ronaldson et al., 2015; 
Wright et al., 2011), the relationship between these traits and treatment in advanced 
cancer has not been explored. Advanced cancer patients may represent a special case for 
the relationship between goal-related personality traits and treatment due to the 
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complicated nature of the disease (i.e., contemplation of EOL, desire for long-term 
survival, messages regarding low likelihood of treatment success) such that the power of 
the EOL situation overwhelms the potential influence of patient personality on treatments 
received (Siminoff & Fetting, 1991). Siminoff and Fetting (1991) examined treatment 
decisions in 100 advanced breast cancer patients. They found that the largest predictor of 
treatment decision was physician recommendation, with 80% of the sample following 
physician recommendation. They further examined factors in patients who did not follow 
physician recommendations and found that these patients were given more specific 
information about benefits of adjuvant therapy, reported higher likelihood and severity of 
side effects of therapy, rated their physician recommendation as less strong, were more 
educated, and were more likely to be risk-takers. Patient personality may only influence 
treatment decisions among those who are given more specific information and less 
direction from their physicians. Consistent with this, Frongillo, Feibelmann, Belkora, 
Lee, and Sepucha (2013) examined shared treatment decision-making in breast cancer 
patients and found that patients who were given a recommendation were less likely to be 
involved in decision-making. Advanced cancer patients may defer to advice from their 
doctors such that standard treatment is employed without being influenced by patient 
personality or EOL goals. In other words, providers may take a more active decision-
making role for patients who are facing the EOL.  
 In addition to physician recommendation, treatment near EOL may be determined 
by the availability of care. Consistent with this, studies have shown that treatment for 
advanced cancer varies by geographical region (Connor, Elwert, Spence, & Christakis, 
2007; Earle et al., 2004; Gill, Laporte, & Coyte, 2013; Lavergne, Johnston, Gao, 
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Dummer, & Rheaume, 2011; Mettlin, Murphy, Cunningham, & Menck, 1997; Sateren et 
al., 2002). This suggests that EOL treatment for advanced cancer, such as hospice 
utilization and intensive use of chemotherapy, is largely determined by availability and 
salience. Scibetta and colleagues (2015) examined utilization of palliative care in 922 
deceased advanced cancer patients. They found that only 32.2% of the sample received a 
palliative care consultation. Of these patients, 31.5% received an early referral and 68.5% 
received a referral in the last months of life. Physician recommendation may reflect 
treatment availability and salience such that only certain treatment options are presented 
to patients. Treatments may be selected according to standards of care in a region and 
without regard to patients’ EOL goals.  
 Despite the predominance of null findings there were some notable trends in the 
relationships between patient personality traits (i.e., goal reengagement, optimism, and 
hope) and treatment intensity. Possible explanations of these trends are presented. 
 In advanced cancer populations, greater goal flexibility is associated with less 
cancer-related distress (Lam et al., 2015; Thompson, Stanton, & Bower, 2013). Goal 
flexibility has not been explored in connection with treatment intensity in advanced 
cancer. I expected patients higher in goal reengagement to be less likely to receive 
intensive treatment near the EOL. However, greater goal reengagement predicted more 
days spent in inpatient setting in the last 30 days of life (Table A21), indicating more 
intensive treatment. Goal reengagement also approached significance in predicting more 
inpatient admissions in the final 30 days of life. This may be explained by greater goal 
reengagement allowing patients to reengage with cure goals despite messages that cure is 
not achievable (i.e., prognostic conversations with doctors and worsening health).  
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In contrast, goal disengagement had a negligible effect size in almost all analyses, 
suggesting that dispositional goal disengagement capacities may not apply to EOL 
situations. Support for this hypothesis is found in Thompson and colleagues’ (2013) 
research on situational and dispositional goal adjustment in advanced breast cancer 
patients. They found dispositional and situational goal disengagement to be unrelated and 
suggested that dispositional goal adjustment may not reflect behavior in cases where the 
unattainable goal is of high value (i.e., life prolongation) and reengagement in alternative 
goals is difficult (i.e., due to worsening QOL or limited alternatives presented by 
physicians). Survival may be of uniquely high value, so that patients are unable to 
disengage from cure goals with the ease they disengage from less valuable goals. 
 Optimism also showed notable trends in predicting treatment intensity near EOL. 
It had a notable effect size and trended toward significance in predicting days spent in an 
inpatient setting in the last 30 days of life (β = -.31, t (69) = -1.99, p = .051; Table A18), 
indicating patients higher in optimism received less intensive treatment. Although this 
relationship was not significant, given the present study’s limited sample size, it is worth 
noting as it suggests this variable may be related to treatment intensity. This is counter to 
the hypothesized relationship, in which optimism was expected to predict greater 
treatment intensity near EOL. Patients who are more optimistic may be less likely to 
pursue cure or life prolongation through intensive treatment near EOL. Consistent with 
this, research has shown that optimists disengage from impossible tasks faster than 
pessimists when alternatives are available (Aspinwall & Richter, 1999). Therefore, 
optimistic patients may more readily accept a life-limiting diagnosis, provided they can 
focus on alternative treatment goals such as symptom management or QOL. 
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 Hope showed significant and notable trends in predicting treatment intensity. I 
predicted patients who are high in hope would be more likely to persist in survival-
focused treatment, and thus have more intensive treatment. Hope predicted days between 
final chemotherapy administration and death, indicating patients with greater hope 
received more intensive treatment (β = -.41, t (66) = -2.31, p = .025; Table A24). Hope 
also had a notable effect size and trended toward significance in predicting time between 
final chemotherapy regimen start and death, also indicating more intensive treatment (β = 
-.33, t (66) = -1.90, p = .062; Table A25). Hope may function differently than optimism 
in the context of EOL because of its focus on the self as an agent of change. Hope 
comprises the ability to identify pathways toward a goal and the agency to use those 
pathways (Snyder, 2002). More hopeful patients may be more willing to accept the low 
likelihood of successful treatment that is typical in advanced lung and GI cancer, such 
that they pursue survival-focused treatment despite worsening health. If the results reflect 
a true relationship, it supports the hypothesis that hope may be maladaptive in advanced 
cancer patients without the option of curative treatment. Because hope is generally 
associated with better treatment outcomes, these findings are especially interesting. 
Aspinwall and Leaf (2002) criticized Snyder’s hope theory and its failure to explain how 
hope may impact behavior when goals are unattainable and there are no alternate 
solutions. The possible maladaptive role of hope in advanced cancer patients merits 
further examination. 
 In the analyses examining EOL clinical encounters as predictors, gender had a 
significant relationships with days spent in an inpatient setting the last 30 days of life (β = 
-.25, t (69) = -2.04, p = .045; Table A13). Women spent an average of 1.90 more days 
36 
 
inpatient compared to men. Gender trended toward significance in predicting inpatient 
admissions in the last 30 days of life; also indicating women received more intensive 
treatment, (β = -.25, t (69) = -1.94, p = .057; Table A14). This is counter to previous 
literature showing men are less likely to utilize hospice and receive more intensive 
treatment near EOL than women (Connor et al., 2007; Miesfeldt, Murray, Lucas, Chang, 
Goodman, & Morden, 2012; Sharma, Prigerson, Penedo, & Maciejewski, 2015). Gender 
showed no relationship in analyses using personality traits as predictors of inpatient days 
or admissions. These results may represent a true relationship between gender and 
treatment intensity that was observable in a simplified model or may represent unreliable 
findings due to methodological issues.  
Conclusion 
 In summary, most planned analyses did not display a relationship between EOL 
clinical encounters and treatment intensity or between personality traits and treatment 
intensity. Interpretation of the results is complicated by reduced power due to sample 
size, measurement error, and restriction of range in both dichotomous and continuous 
variables. The results of all analyses should be viewed with reduced power in mind. 
Because of the small sample size and uneven frequency distributions in the predictor 
variables, it is particularly difficult to interpret the relationship between EOL clinical 
encounter variables and treatment intensity.  
However, there was some evidence of a relationship between patient personality 
and treatment intensity. Greater goal reengagement predicted more inpatient days in an 
emergent care setting in the last 30 days of life, indicating more intensive treatment. This 
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is counter to the hypothesized relationship. I theorize that greater goal reengagement 
capacities may allow patients to reengage with life-prolongation and cure goals despite 
worsening health. However, because goal flexibility has not been explored in the context 
of intensive EOL treatment for advanced cancer it is difficult to make conclusions about 
this relationship. The relationship between goal flexibility and EOL treatment in 
advanced cancer should be explored further. 
Optimism also showed a notable effect size in predicting inpatient days; however 
the relationship was not significant. Great optimism was associated with fewer inpatient 
days near EOL, indicating less intensive treatment. This is also counter to the 
hypothesized relationship. I theorize that optimists may be more able to disengage from 
cure goals and engage in symptom management goals that optimize QOL. Because 
optimists endorse the idea that good, as opposed to bad things will happen in the future 
(Scheier & Carver, 1985), they may be more able to accept a life-limiting diagnosis with 
the expectation that they and their family will be alright whatever the outcome. The 
relationship between optimism and EOL treatment in advanced cancer also warrants 
further study.  
Finally, greater hope predicted fewer days between final chemotherapy 
administration and death. Hope also had a notable effect size in an analysis examining 
days between final chemotherapy regimen start and death. This suggests a positive 
relationship between hope and treatment intensity near EOL. This relationship confirms 
the hypothesis that hope would predict more intensive treatment. How hope drives goal-
directed behavior when goal achievement is impossible has not been well explained by 
SRT (Aspinwall & Leaf, 2002). Hope may be maladaptive in situations where goals are 
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of high value but expectancy of goal achievement is low. Because hope is largely 
considered adaptive in the context of cancer and cancer treatment, these findings have 
important implications. Patients high in trait hope appear to be more likely to pursue 
survival focused treatment even when expectancy of success is low. This knowledge may 
impact how physicians relate prognostic information to patients.  
As this study was exploratory in nature, it is worth noting the significant and 
trending relationships between goal-related personality traits and treatment intensity 
despite analyses being underpowered. Hope, optimism, and goal flexibility have not 
previously been examined as predictors of EOL treatment intensity in advanced cancer. 
Further research examining the relationship between personality traits and treatment 
intensity is warranted as knowledge of how goal-related personality traits impact 
treatment intensity near EOL may help physicians to effectively communicate prognostic 
and treatment information to their patients. 
Limitations 
There are several limitations worth noting. The small sample size limited the 
power of the analyses. However, the methods and analysis employed may still prove 
fruitful as this study is exploratory in nature and aims to detect trends in treatment choice 
in advanced cancer patients. 
The content of prognostic conversations between physicians and patients was not 
recorded, such that the extent and accuracy of the communicated prognostic information 
is not known. 
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The external validity of this study may be affected by volunteer bias. Volunteers 
have shown differences in impulsivity and willingness to disclose when compared to non-
volunteers (Gustavsson, Asberg, & Schalling, 1997; Hood & Back, 1971). Those who 
participate may differ significantly from those who refused participation such that 
findings from this study may not generalize to the larger advanced cancer population. In 
this study, consenters were younger than refusers. Therefore, it is likely that this study, 
similar to other studies in cancer populations, may have been subject to “healthy 
volunteer bias.” Patients who were in better general health may have been more willing 
to participate than patients who were more ill, biasing the sample to participants with 
lower symptom burden and longer survival time (Gill, Laporte, & Coyte, 2013; Preston et 
al., 2013).  
Medical record information is incomplete and may be inaccurate. This is often a 
problem encountered in studies that require medical record review (Sikorskii et al., 
2012). Missing and unknown information is a common problem in research examining 
health care information in cancer patients, particularly among those approaching the EOL 
(Gill, Laporte, & Coyte, 2013; Preston et al., 2013). The issue of missing and unknown 
event data was particularly evident in examining hospice enrollment in this sample, as 
hospice enrollment was unknown for a large portion of the sample. Unknown event data 
can result in under- or overestimating event occurrence and loss of power in statistical 
analysis (Gill, Laporte, & Coyte, 2013; Prestion et al., 2013). However, the methods of 
data collection and variables examined in the study have been shown to be good 
indicators of treatment intensity in this population (Earle et al., 2003). 
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Self-report measures may be affected by social desirability (Podsakoff et al., 
2003). Research has shown that cancer patients may be at particular risk for biased 
reporting on self-report measures (Breetvelt & Van Dam, 1991; O’Leary et al., 2007). 
For example, childhood cancer survivors display a tendency to underreport QOL issues 
and emotional difficulties compared to healthy controls (O’leary et al., 2007). The culture 
associated with cancer emphasizes hope and staying positive (Sulmasy et al., 2010), such 
that participants may feel pressure give the “right” answer on measures of hope, 
optimism, and goal flexibility. This would bias the assessment of these variables, restrict 
range, and thereby reduce the association between goal-related personality traits and 
treatment intensity.  
Finally, the external validity of the study is limited by sample demographics, 
types of cancer studied, and the recruitment location. Subjects recruited from a tertiary 
cancer center may differ from patients treated in other settings by their treatment goals 
and care received (Haas et al., 2007; Lavergne, Johnston, Gao, Dummer, & Rheaume, 
2011; Sateren et al., 2002). These issues may limit the generalizability of these findings 
to the broader advanced cancer patient population. 
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Appendix A: Tables 
 
Table A1. Electronic Medical Record Coding 
 Information regarding various indicators of intensive treatment were noted in 
multiple sections of the medical record, including: 1) scheduled clinic visit notes; 2) 
social worker notes; 3) chaplain notes; 4) ICU/ER admission notes; 5) ICU/ER discharge 
notes; 6) nursing encounter notes; 7) intravenous drug administration records; 8) 
uploaded legal documents; 9) uploaded doctors’ correspondence; 10) uploaded 
correspondence between health care sites; and 11) patient correspondence.  
Variable Electronic source document Example  
Enrollment in 
hospice 
Scheduled clinic visit notes 
(included in disease history 
section and/or current 
treatment plan section), social 
worker notes, chaplain notes, 
ICU/ER admission/discharge 
notes, nursing encounter 
notes, uploaded legal 
documents, uploaded doctors’ 
correspondence, uploaded 
correspondence between 
health care sites, and patient 
correspondence. 
Physician note: “I discussed with her 
options including best supportive care 
with or without hospice services…” 
 
Prognostic 
conversation  
Scheduled clinic visit notes 
(included in disease history 
section and/or current 
treatment plan section) 
Physician note: “The patient was 
advised regarding the risk and 
benefits of therapy and the side 
effects.  In addition, I did discuss 
with the patient and her family her 
prognosis.  Unfortunately, she has 
extensive extra-pulmonary small cell 
carcinoma for which therapy can 
prolong life and is palliative, 
however, is not curative.  She took 
this information extremely well, and 
has a clear understanding about the 
current situation.  We will plan on 
seeing her back in about 3 weeks' 
time or sooner should she have any 
problems.” 
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Table A1. continued 
Performance 
status 
Scheduled clinic visit notes 
(included in disease history 
section and/or current 
treatment plan section) 
Physician note: “ECOG 
performances status is 1.” 
 
Chemotherapy 
administration  
Scheduled clinic visit notes 
(included in disease history 
section and/or current 
treatment plan section), 
intravenous drug 
administration records, 
uploaded doctors’ 
correspondence, and uploaded 
correspondence between 
health care sites 
Physician note: “The patient 
received four 
cycles of carboplatin and gemcitabine 
with an excellent subjective and 
objective response.” 
 
ICU/ER ICU/ER admission/discharge 
notes, uploaded 
correspondence between 
health care sites, and patient 
correspondence 
Length of stay noted on discharge 
form. 
e.g.,  
DATE OF ADMISSION:  
07/08/2010 
DATE OF DISCHARGE:  
07/14/2010 
Hospitalization  Scheduled clinic visit notes 
(included in disease history 
section and/or current 
treatment plan section), 
ICU/ER admission/discharge 
notes, uploaded 
correspondence between 
health care sites, and patient 
correspondence 
Length of stay noted on discharge 
form.  
e.g.,  
DATE OF ADMISSION:  
09/08/2010 
DATE OF DISCHARGE:  
09/12/2010 
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Table A2. Demographics  
Variable   
M(SD) 
Age   60.3(11.9) 
 N % 
Gender   
Male 38 50.0 
Female 38 50.0 
Cancer type   
Lung 34 44.7 
GI 42 55.3 
Race   
Caucasian 71 93.4 
African American 3 3.9 
Missing 2 2.6 
Education   
Some high school or less 5 6.6 
High school graduate 24 31.6 
Some college 12 15.8 
College graduate 11 14.5 
Some graduate or professional school 7 9.2 
Graduate or professional school degree 13 17.1 
Missing 4 5.3 
Marital status   
Single never married 3 3.9 
Married or partnered 53 69.7 
Separated 3 3.9 
Divorced 7 9.2 
Widowed  6 7.9 
Missing 4 5.3 
Insurance type    
None  2 2.6 
Fee-for-service 2 2.6 
Managed care  26 34.2 
Medicare 35 46.1 
Medicaid 5 6.6 
Missing 6 7.9 
Performance status   
0 25 32.9 
1 39 51.3 
2 11 14.5 
3 1 1.3 
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Table A3. Characteristics of Dichotomous Predictor and Outcome Variables 
Dichotomous Variable Yes (N) % 
EMR documented EOL clinical encounter 68 89.50 
Patient-reported EOL clinical encounter 6 8.50 
Intensive treatment 29 38.20 
Chemotherapy within 30 days of death or new 
chemotherapy regimen start within 60 days of death 
14 18.40 
Emergent care use within 30 days of death 23 30.30 
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Table A4. Characteristics of Continuous Predictor and Outcome Variables 
Continuous Variable Mean SD Skew Kurtosis 
Hope 51.76 7.46 -.69 .62 
Optimism 17.03 3.49 -.20 .21 
Goal disengagement 10.52 2.68 -.61 -.32 
Goal reengagement 21.29 4.79 -.14 -.46 
Day spent in the ER/ICU or hospitalized 
within 30 days of death 
2.39 4.22 2.78 9.64 
Admissions to the ER/ICU or hospital 
within 30 days of death 
.62 .78 1.14 .73 
Days between hospice admission and 
death 
42.20 70.25 3.20 11.72 
Days between last chemotherapy 
administration and death 
149.79 209.76 3.19 11.78 
Days between final chemotherapy 
regimen start and death 
240.36 231.25 2.47 7.56 
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Table A5. Correlations 
Zero order correlations between predictor and control variables 
Variable 1 2 3 4 5 6 7 8 9 10 
1. Hope  .60** -.49** .56** .01 .08 -.03 -.01 -.06 -.41** 
2. Optimism   -.38** -.50 .04 .19 .04 .01 -.12 -.39** 
3. Goal disengagement    -.47** .05 -.10 .20 .07 .09 .17 
4. Goal reengagement     .03 .06 -.10 -.18 -.04 -.13 
5. EMR documented EOL 
conversation 
     .10 .22 -.26* .11 -.10 
6. Patient-reported EOL 
goals conversation 
      .08 -.10 .80 -.01 
7. Age        -.12 .27* -.06 
8. Gender         -.04 .02 
9. Performance status          .16 
10. Distress           
Note. *p < .05. **p < .01. 
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Table A6. Research Question 1, Logistic Regression Analyses  
 
Analyses Predictor 
Variables 
Controls  Outcome Variable 
1st logistic 
regression 
(Table 10)  
 
EMR documented 
EOL conversation;  
Patient-reported 
EOL goals 
conversation 
Age, Gender; 
Performance 
status; Distress 
Use of intensive 
treatment 
2nd logistic 
regression 
(Table A11) 
 
EMR documented 
EOL conversation;  
Patient-reported 
EOL goals 
conversation 
Age; Gender; 
Performance 
status; Distress 
Chemotherapy use 
near EOL 
 
 
 
3rd logistic 
regression 
(Table A12) 
 
EMR documented 
EOL conversation; 
Patient-reported 
EOL goals 
conversation 
Age; Gender; 
Performance 
status; Distress 
Emergent care use 
within 30 days of 
death 
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Table A7. Research Question 1, Linear Regression Analyses  
 
Analyses Predictor 
Variables 
Controls  Outcome Variable 
1st linear 
regression 
(Table A13) 
 
EMR documented 
EOL 
conversation;  
Patient-reported 
EOL goals 
conversation 
Age; Gender; 
Performance 
status; Distress 
Total inpatient days 
within 30 days of 
death 
2nd linear 
regression 
(Table A14) 
 
EMR documented 
EOL 
conversation; 
Patient-reported 
EOL goals 
conversation 
Age; Gender; 
Performance 
status; Distress 
Total inpatient 
admissions within 30 
days of death 
3rd linear 
regression 
(Table A15) 
 
EMR documented 
EOL 
conversation;  
Patient-reported 
EOL goals 
conversation 
Age; Gender; 
Performance 
status; Distress 
Days on hospice 
4th linear 
regression 
(Table A16) 
EMR documented 
EOL 
conversation; 
Patient-reported 
EOL goals 
conversation 
Age; Gender; 
Performance 
status; Distress 
Days between final 
chemotherapy 
administration and 
death 
 
5th linear 
regression 
(Table A17) 
 
EMR documented 
EOL 
conversation; 
Patient-reported 
EOL goals 
conversation 
Age; Gender; 
Performance 
status; Distress 
Days between final 
chemotherapy regimen 
start and death 
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Table A8. Research Question 2, Logistic Regression Analyses  
 
Analyses Predictor Variables Controls  Outcome Variable 
1st logistic 
regression 
(Table A18)  
 
Hope; Optimism; Goal 
disengagement; Goal 
reengagement 
Age; Gender; 
Performance 
status; Distress 
Use of intensive 
treatment 
2nd logistic 
regression 
(Table A19) 
 
Hope; Optimism; Goal 
disengagement; Goal 
reengagement 
Age; Gender; 
Performance 
status; Distress 
Chemotherapy use 
near EOL 
3rd logistic 
regression 
(Table A20) 
 
Hope; Optimism; Goal 
disengagement; Goal 
reengagement 
Age; Gender; 
Performance 
status; Distress 
Emergent care use 
within 30 days of 
death 
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Table A9. Research Question 2, Linear Regression Analyses  
Analyses Predictor Variables Controls  Outcome Variable 
1st linear 
regression 
(Table A21) 
 
Hope; Optimism; 
Goal disengagement; 
Goal reengagement 
Age; Gender; 
Performance 
status, Distress 
Total inpatient days 
within 30 days of 
death 
2nd linear 
regression 
(Table A22) 
 
Hope; Optimism; 
Goal disengagement, 
Goal reengagement 
Age; Gender; 
Performance 
status; Distress 
Total inpatient 
admissions within 30 
days of death 
3rd linear 
regression 
(Table A23) 
 
Hope; Optimism; 
Goal disengagement; 
Goal reengagement 
Age; Gender; 
Performance 
status; Distress 
Days on hospice 
4th linear 
regression 
(Table A24) 
Hope; Optimism; 
Goal disengagement; 
Goal reengagement 
Age; Gender; 
Performance 
status; Distress 
Days between final 
chemotherapy 
administration and 
death 
 
5th linear 
regression 
(Table A25) 
 
Hope; Optimism; 
Goal disengagement; 
Goal reengagement 
Age; Gender; 
Performance 
status; Distress 
Days between final 
chemotherapy 
regimen start and 
death 
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Table A10. Research Question 1: Summary of Hierarchical Logistic Regression Analysis 
for EOL Clinical Encounters Predicting Use of Intensive Treatment near End of Life (N = 
69) 
Variable B S.E. O.R. 95% CI p 
Step 1      
Age -0.02 0.02 0.98 0.94-1.03 0.479 
Gender -0.90 0.55 0.40 0.14-1.20 0.102 
Performance status 0.89 0.45 2.43 1.00-5.90 0.049 
Distress -0.02 0.05 0.98 0.90-1.07 0.660 
Step 2      
EMR documented EOL  
conversation A 
 
-0.45 0.97 1.04 0.15-7.00 0.970 
Patient-reported EOL goals 
conversation B 0.70 0.93 0.64 0.10-3.93 0.625 
Note: For step 2, Nagelkerke R2 = .153; model chi square = 8.230, p > .05, df = 6. Hosmer and Lemeshow 
(H-L) goodness of fit statistic chi square = 12.980, p > .05, df = 8. Gender is coded so that 0 = female and 1 
= male. The dependent variable is coded so that 0 = no intensive treatment indicator and 1 = presence of an 
intensive treatment indicator. A n = 63. B n = 6. Bolded line indicates p < .05. 
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Table A11. Research Question 1: Summary of Hierarchical Logistic Regression Analysis 
for EOL Clinical Encounters Predicting Chemotherapy Use near End of Life (N = 69) 
Variable B S.E. O.R. 95% CI p 
Step 1      
Age -0.01 0.03 0.99 0.94-1.05 0.680 
Gender -0.46 0.66 0.63 0.17-2.32 0.491 
Performance status 0.33 0.48 1.39 0.54-3.56 0.497 
Distress -0.04 0.06 0.97 0.87-1.08 0.516 
Step 2      
EMR documented EOL  
conversation A 
 
0.01 1.21 1.01 0.10-10.70 0.996 
Patient-reported EOL goals  
conversation B 
0.78 0.95 2.19 0.34-13.98 0.408 
Note: For step 2, Nagelkerke R2 = .050; model chi square = 2.182, p > .05, df = 6. H-L goodness of fit 
statistic chi square = 8.809, p > .05, df = 8. Gender is coded so that 0 = female and 1 = male. The dependent 
variable is coded so that 0 = receiving no chemotherapy within these periods and 1 = receiving 
chemotherapy within these periods. A n = 63. B n = 6. 
  
73 
Table A12. Research Question 1: Summary of Hierarchical Logistic Regression Analysis 
for EOL Clinical Encounters Predicting Emergent Care Use within 30 Days of Death (N 
= 69) 
Variable B S.E. O.R. 95% CI p  
Step 1      
Age -0.02 0.03 0.98 0.93-1.03 0.375 
Gender -1.01 0.61 0.36 0.11-1.20 0.097 
Performance status 1.12 0.50 3.06 1.14-8.20 0.027 
Distress 0.04 0.05 1.04 0.94-1.15 0.497 
Step 2      
EMR documented EOL  
conversation A 
 
0.84 1.25 2.30 0.20-26.73 0.504 
Patient-reported EOL goals  
conversation B 
-1.13 1.18 0.32 0.03-3.26 0.339 
Note: For step 2, Nagelkerke R2 = .242; model chi square = 12.779, p < .05, df = 6. H-L goodness of fit 
statistic chi square = 6.683, p > .05, df = 8. Gender is coded so that 0 = female and 1 = male. The dependent 
variable is coded so that 0 = no emergent care use and 1 = emergent care use. A n = 63. B n = 6. Bolded line 
indicates p < .05. 
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Table A13. Research Question 1: Summary of Hierarchical Linear Regression Analysis 
for EOL Clinical Encounters Predicting Total Days Inpatient in the ICU/ER and/or 
Hospitalized within 30 Days of Death (N = 69) 
Variable B S.E. β t p 
Step 1      
Age -0.03 0.04 -0.10 -0.75 0.455 
Gender -1.90 0.93 -0.25 -2.04 0.045 
Performance status 0.78 0.70 0.14 1.11 0.270 
Distress -0.04 0.08 -0.06 -0.52 0.603 
Step 2      
EMR documented EOL  
conversation A  
 
0.25 1.57 0.02 0.16 0.876 
Patient-reported EOL goals  
conversation B 
-2.41 1.60 -0.18 -1.50 0.139 
Note: R2 = .086 for step 1; ΔR2 = .032 for step 2 (p > .05). Gender is coded so that 0 = female and 1 = male. 
A n = 63. B n = 6. Bolded line indicates p < .05. 
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Table A14. Research Question 1: Summary of Hierarchical Linear Regression Analysis 
for EMR Documented EOL Clinical Encounters Predicting Inpatient Admissions within 
30 Days of Death (N = 69) 
Variable B S.E. β t p 
Step 1      
Age -0.01 0.01 -0.08 -0.58 0.566 
Gender -0.38 0.20 -0.25 -1.94 0.057 
Performance status 0.15 0.14 0.13 1.03 0.309 
Distress 0.00 0.02 -0.02 -0.18 0.856 
Step 2      
EMR documented EOL  
conversation A 
 
-0.15 0.33 -0.06 -0.43 0.659 
Patient-reported EOL goals  
conversation B 
-0.22 0.65 -0.08 -0.64 0.523 
Note: R2 = .065 for step 1; ΔR2 = .010 for step 2 (p > .05). Gender is coded so that 0 = female and 1 = male. 
A n = 63. B n = 6.   
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Table A15. Research Question 1: Summary of Hierarchical Linear Regression Analysis 
for EOL Clinical Encounters Predicting Days on Hospice (N = 42) 
Variable B S.E. β t p 
Step 1      
Age 0.50 0.85 0.10 0.59 0.560 
Gender 25.80 19.52 0.21 1.32 0.195 
Performance status 17.68 14.20 0.20 1.25 0.222 
Distress 2.03 1.47 0.21 1.38 0.178 
Step 2      
EMR documented EOL  
conversation A 
 
38.56 61.38 0.10 0.63 0.534 
Patient-reported EOL goals  
conversation B 
53.50 31.33 0.26 1.71 0.097 
Note: R2 = .104 for step 1; ΔR2 = .037 for step 2 (p > .05). Gender is coded so that 0 = female and 1 = male. 
A n = 41. B n = 4.   
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Table A16. Research Question 1: Summary of Hierarchical Linear Regression Analysis 
for EMR Documented EOL Clinical Encounters Predicting Days Between Final 
Chemotherapy Administration and Death (N = 66) 
Variable B S.E. β t p 
Step 1      
Age 0.72 1.79 0.05 0.41 0.687 
Gender -2.20 41.59 -0.01 -0.05 0.958 
Performance status -36.26 31.86 -0.16 -1.14 0.260 
Distress 2.91 3.51 0.11 0.83 0.410 
Step 2      
EMR documented EOL  
conversation A 
 
76.30 74.07 0.14 1.03 0.307 
Patient-reported EOL goals  
conversation B 
-71.87 71.02 -0.13 -1.01 0.316 
Note: R2 = .023 for step 1; ΔR2 = .031 for step 2 (p > .05). Gender is coded so that 0 = female and 1 = male. 
A n = 66. B n = 6. 
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Table A17. Research Question 1: Summary of Hierarchical Linear Regression Analysis 
for EOL Clinical Encounters Predicting Days between Final Chemotherapy Regimen 
Start and Death (N = 66) 
Variable B S.E. β t p 
Step 1      
Age 0.18 2.11 0.01 0.09 0.931 
Gender -5.89 48.90 -0.02 -0.12 0.905 
Performance status -40.79 37.47 -0.15 -1.09 0.281 
Distress -0.99 4.12 -0.03 -0.24 0.811 
Step 2      
EMR documented EOL  
conversation A 
 
27.11 87.09 0.04 0.31 0.757 
Patient-reported EOL goals  
conversation B 
-112.17 83.50 -0.17 -1.34 0.184 
Note: R2 = .027 for step 1; ΔR2 = .030 for step 2 (p > .05). Gender is coded so that 0 = female and 1 = male. 
A n = 66. B n = 6.  
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Table A18. Research Question 2: Summary of Hierarchical Logistic Regression Analysis 
for Personality Variables Predicting Use of Intensive Treatment Near EOL (N = 70) 
Variable B S.E. O.R. 95% C.I. p 
Step 1      
Age -0.01 0.03 1.00 0.94-1.05 0.839 
Gender -0.80 0.57 0.45 0.15-1.37 0.160 
Performance Status 0.79 0.46 2.20 0.90-5.40 0.086 
Distress -0.02 0.06 0.98 0.88-1.10 0.723 
Step 2      
Hope 0.03 0.06 1.03 0.91-1.15 0.665 
Optimism -0.09 0.11 0.92 0.74-1.13 0.407 
Goal disengagement -0.10 0.12 0.90 0.71-1.15 0.400 
Goal reengagement 0.12 0.08 1.13 0.97-1.32 0.118 
Note: For step 2, Nagelkerke R2 = .255; model chi square = 14.474, p > .05, df = 8; H-L goodness of fit 
statistic chi square = 10.114, p > .05, df = 8. Gender is coded so that 0 = female and 1 = male. The 
dependent variable is coded so that 0 = no intensive treatment indicator and 1 = presence of an intensive 
treatment indicator. 
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Table A19. Research Question 2: Summary of Hierarchical Logistic Regression Analysis 
for Personality Variables Predicting Chemotherapy Use near EOL (N = 70) 
Variable B S.E. O.R. 95% CI p 
Step 1      
Age -0.01 0.03 0.99 0.93-1.05 0.659 
Gender -0.50 0.67 0.61 0.16-2.27 0.459 
Performance Status 0.25 0.48 1.28 0.50-3.28 0.608 
Distress -0.05 0.07 0.95 0.84-1.09 0.476 
Step 2      
Hope 0.03 0.07 1.03 0.90-1.17 0.711 
Optimism -0.05 0.12 0.95 0.75-1.20 0.663 
Goal disengagement 0.14 0.15 1.15 0.85-1.55 0.365 
Goal reengagement 0.09 0.09 1.10 0.92-1.30 0.301 
Note: For step 2, Nagelkerke R2 = .076; model chi square = 3.348, p > .05, df = 8; H-L goodness of fit 
statistic chi square = 8.618, p > .05, df = 8. Gender is coded so that 0 = female and 1 = male. The dependent 
variable is coded so that 0 = receiving no chemotherapy within these periods and 1 = receiving 
chemotherapy within these periods. 
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Table A20. Research Question 2: Summary of Hierarchical Logistic Regression Analysis 
for Personality Variables Predicting Emergent Care Use within 30 Days of Death (N = 
70) 
Variable B S.E. O.R. 95% CI p 
Step 1      
Age -0.01 0.03 0.99 0.94-1.05 0.815 
Gender -0.95 0.64 0.39 0.11-1.36 0.137 
Performance Status 0.97 0.52 2.64 0.95-7.28 0.062 
Distress 0.03 0.06 1.03 0.91-1.17 0.622 
Step 2      
Hope 0.05 0.07 1.05 0.92-1.21 0.447 
Optimism -0.18 0.13 0.84 0.65-1.07 0.149 
Goal disengagement -0.07 0.14 0.93 0.71-1.23 0.621 
Goal reengagement 0.16 0.09 1.17 0.98-1.40 0.081 
Note: For step 2, Nagelkerke R2 = .335; model chi square = 18.612, p < .05, df = 8; H-L goodness of fit 
statistic chi square = 5.575, p > .05, df = 8. Gender is coded so that 0 = female and 1 = male. The dependent 
variable is coded so that 0 = no emergent care use and 1 = emergent care use.  
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Table A21. Research Question 2: Summary of Hierarchical Linear Regression Analysis 
for Personality Variables Predicting Total Days Inpatient in the ICU/ER and/or 
Hospitalized within 30 Days of Death (N = 70) 
Variable B S.E. β t p 
Step 1      
Age -0.01 0.04 -0.04 -0.33 0.744 
Gender -1.39 0.88 -0.19 -1.58 0.119 
Performance status 0.46 0.65 0.09 0.71 0.482 
Distress -0.05 0.08 -0.08 -0.58 0.568 
Step 2      
Hope  0.07 0.09 0.14 0.83 0.407 
Optimism -0.33 0.16 -0.31 -1.99 0.051 
Goal disengagement 0.02 0.20 0.01 0.10 0.920 
Goal reengagement 0.30 0.12 0.38 2.54 0.014 
Note: R2 = .087 for step 1; ΔR2 = .134 for step 2 (p = .04). Gender is coded so that 0 = female and 1 = male. 
Bolded line indicates p < .05.  
83 
Table A22. Research Question 2: Summary of Hierarchical Linear Regression Analysis 
for Personality Variables Predicting Inpatient Admissions within 30 Days of Death (N = 
70) 
Variable B S.E. β t p 
Step 1      
Age -0.00 0.01 -0.04 -0.34 0.732 
Gender -0.29 0.19 -0.18 -1.49 0.141 
Performance status 0.12 0.14 0.12 0.87 0.389 
Distress 0.01 0.02 0.07 0.50 0.616 
Step 2      
Hope  0.01 0.02 0.13 0.75 0.455 
Optimism -0.01 0.04 -0.04 -0.28 0.782 
Goal disengagement -0.02 0.04 -0.06 -0.39 0.697 
Goal reengagement 0.05 0.03 0.27 1.76 0.083 
Note: R2 = .072 for step 1; ΔR2 = .120 for step 2 (p > .05). Gender is coded so that 0 = female and 1 = male.   
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Table A23. Research Question 2: Summary of Hierarchical Linear Regression Analysis 
for Personality Variables Predicting Days on Hospice (N = 42) 
Variable B S.E. β t p 
Step 1      
Age -0.62 1.21 0.10 0.51 0.612 
Gender 1.16 27.81 0.02 0.04 0.967 
Performance status 21.49 17.83 0.29 1.65 0.108 
Distress 0.06 2.43 0.01 0.02 0.981 
Step 2      
Hope  -1.45 2.54 -0.15 -0.57 0.571 
Optimism 3.67 5.12 0.16 0.71 0.479 
Goal disengagement 4.52 6.48 0.15 0.70 0.490 
Goal reengagement -4.63 3.88 -0.28 -1.19 0.241 
Note: R2 = .107 for step 1; ΔR2 = .110 for step 2 (p > .05). Gender is coded so that 0 = female and 1 = male.   
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Table A24. Research Question 2: Summary of Hierarchical Linear Regression Analysis 
for Personality Variables Predicting Days between Final Chemotherapy Administration 
and Death (N = 67) 
Variable B S.E. β t p 
Step 1      
Age 0.36 1.75 0.03 0.21 0.836 
Gender -8.79 38.74 -0.03 -0.23 0.821 
Performance status -23.38 29.40 -0.10 -0.80 0.430 
Distress -1.18 3.68 -0.05 -0.32 0.749 
Step 2      
Hope  -8.98 3.89 -0.41 -2.31 0.025 
Optimism 6.35 7.23 0.14 0.88 0.384 
Goal disengagement -10.48 8.52 -0.18 -1.23 0.224 
Goal reengagement -7.95 5.33 -0.23 -1.49 0.142 
Note: R2 = .025 for step 1; ΔR2 = .158 for step 2 (p = .034). Gender is coded so that 0 = female and 1 = 
male. Bolded line indicates p < .05. 
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Table A25. Research Question 2: Summary of Hierarchical Linear Regression Analysis 
for Personality Variables Predicting Days between Final Chemotherapy Regimen Start 
and Death (N = 67) 
Variable B S.E. β t p 
Step 1      
Age 0.47 2.05 0.03 0.23 0.821 
Gender 3.17 45.30 0.01 0.07 0.944 
Performance status -38.72 34.39 -0.15 -1.13 0.265 
Distress -6.50 4.30 -0.21 -1.51 0.137 
Step 2      
Hope  -8.65 4.55 -0.33 -1.90 0.062 
Optimism -7.59 8.46 -0.15 -0.90 0.373 
Goal disengagement -18.72 9.97 -0.27 -1.88 0.065 
Goal reengagement -5.32 6.24 -0.13 -0.85 0.397 
Note: R2 = .032 for step 1; ΔR2 = .165 for step 2 (p = .026). Gender is coded so that 0 = female and 1 = 
male. 
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Appendix B: Figures 
 
  
Patient Factors (Hope, 
Optimism, Goal 
flexibility) 
EOL Clinical 
Encounters (Self-report 
and Chart abstraction)  
Treatment (Survival-focused 
or Symptom-directed)  
 
Figure B1. Expected Relationships 
Patient factors and EOL clinical encounters may impact treatment decisions at EOL. 
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170 eligible patients identified 
 
84 patients consented; 
70 completed surveys 
36 patients refused; 
11 deceased; 
22 lost to follow-up 
76 clinical data; 
70 completed surveys 
8 patients alive at 
final data collection, 
excluded from 
analysis 
 
153 mailed introductory packet 
17 not given packet: 
15 unable to 
approach; 
2 at MD’s discretion  
Figure B2. Participant Recruitment 
Participant recruitment March 2010-July 2011 
 
